NEW YORK: The latest research on Eli Lilly’s newly approved weight loss drug, Zepbound, reveals that patients may face significant weight regain after stopping the treatment, indicating potential long-term dependence on such medications. The study, published in the Journal of the American Medical Association, focused on tirzepatide, the active compound in Zepbound.
The trial included 670 adults who received weekly injections of tirzepatide, resulting in a noteworthy mean weight loss of 20.9 percent after 36 weeks. The participants were then divided into two groups, with one continuing Zepbound, while the other received a placebo. At the 88-week mark, those on the placebo experienced almost half of the weight regain, ending 9.9 percent lower than their baseline. Conversely, the group on Zepbound continued to lose weight, concluding 25.3 percent lower than their initial weight.
Significance of Pharmacotherapy to Prevent Weight Regain
The study’s authors, led by Louis Aronne at Weill Cornell Medicine, stressed the importance of ongoing pharmacotherapy to prevent weight regain and maintain weight reduction. This research aligns with previous trials demonstrating substantial weight regain after stopping the use of potent anti obesity medications, including GLP-1 agonists like semaglutide, which is found in Novo Nordisk’s Ozempic and Wegovy.
GLP-1 agonists mimic the function of a hormone that regulates insulin secretion, slows stomach emptying, and suppresses appetite. Zepbound, in addition to tirzepatide, contains another molecule that acts similarly to the gut hormone GIP.
In response to the findings, Lilly’s Jeff Emmick highlighted the chronic nature of obesity, emphasizing the need for ongoing treatment even after weight goals are achieved. GLP-1 agonists have demonstrated benefits in reducing the risk of cardiovascular disease associated with obesity, but concerns about gastrointestinal problems and the long-term use of these drugs persist.
While cost can be a deterrent, with Zepbound priced at $1,059.87 per month and limited insurance coverage, experts emphasize the need for a comprehensive understanding of obesity as a chronic disease requiring continued care and treatment.
